www.finanzen.net bietet Finanznachrichten zum weltweiten Boersengeschehenhttp://www.finanzen.netde-definanzen.net GmbHhttp://images.finanzen.net/images/finanzen_net_neu.gifhttp://www.finanzen.nethttp://www.finanzen.net/nachricht/Robbins-Umeda-LLP-Announces-Investigation-of-KV-Pharmaceutical-Company-734350 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Robbins Umeda LLP has commenced an investigation into possible mismanagement of KV Pharmaceutical Company ("KV" or the "Company") (NYSE: KV-A). ...http://www.finanzen.net/nachricht/Robbins-Umeda-LLP-Announces-Investigation-of-KV-Pharmaceutical-Company-734350http://www.finanzen.net/nachricht/aktien/Roy-Jacobs-Associates-Announces-That-a-Class-Action-Has-Been-Filed-Against-KV-Pharmaceutical-Company-Alleging-Securities-Law-Violations-420511 Roy Jacobs Associates announces that a class action has been commenced on behalf of shareholders who acquired KV Pharmaceutical Company ("KV" or the "Company") Class A Common Stock (NYSE: KV-A), Class B Common Stock ...http://www.finanzen.net/nachricht/aktien/Roy-Jacobs-Associates-Announces-That-a-Class-Action-Has-Been-Filed-Against-KV-Pharmaceutical-Company-Alleging-Securities-Law-Violations-420511http://www.finanzen.net/nachricht/aktien/KV-Pharmaceutical-to-Host-Conference-Call-Introducing-Interim-CEO-David-Van-Vliet-418769 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} .bwunderlinestyle {text-decoration: underline} --> </style> KV Pharmaceutical Company (NYSE: KV-A) will hold an analyst conference call at 4 p.m. EST (3 p.m. CST) ...http://www.finanzen.net/nachricht/aktien/KV-Pharmaceutical-to-Host-Conference-Call-Introducing-Interim-CEO-David-Van-Vliet-418769http://www.finanzen.net/nachricht/aktien/KV-Pharmaceutical-Announces-Changes-in-Senior-Management-418100 <style type="text/css"> <!-- .bwunderlinestyle {text-decoration: underline} --> </style> KV Pharmaceutical Company (NYSE: KV-A) announced today that the Board of Directors has terminated, for cause, the employment agreement of the ...http://www.finanzen.net/nachricht/aktien/KV-Pharmaceutical-Announces-Changes-in-Senior-Management-418100http://www.finanzen.net/nachricht/aktien/Coughlin-Stoia-Geller-Rudman-Robbins-LLP-Files-Class-Action-Suit-against-KV-Pharmaceutical-Company-416539 <style type="text/css"> <!-- .bwtextaligncenter {text-align: center} --> </style> Coughlin Stoia Geller Rudman Robbins LLP ("Coughlin Stoia”) (<a href="http://cts.businesswire.com/ct/CT?id=smartlinkurl=http%3A%2F%2Fwww.csgrr.com%2Fcas ...http://www.finanzen.net/nachricht/aktien/Coughlin-Stoia-Geller-Rudman-Robbins-LLP-Files-Class-Action-Suit-against-KV-Pharmaceutical-Company-416539http://www.finanzen.net/nachricht/aktien/KV-Begins-Shipping-Evamist-TM-to-Wholesalers-654100ST. LOUIS, April 14 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company , a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical ...http://www.finanzen.net/nachricht/aktien/KV-Begins-Shipping-Evamist-TM-to-Wholesalers-654100http://www.finanzen.net/nachricht/aktien/KV-Signs-Licensing-Agreement-for-the-Marketing-of-Clindesse-TM-in-18-Eastern-European-Countries-571119ST. LOUIS, Dec. 1 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company announced today that it has concluded a long-term licensing agreement with Gedeon Richter to market in 18 Eastern European countries KV's Clindesse(TM) (clindamycin phosphate) vaginal ...http://www.finanzen.net/nachricht/aktien/KV-Signs-Licensing-Agreement-for-the-Marketing-of-Clindesse-TM-in-18-Eastern-European-Countries-571119http://www.finanzen.net/nachricht/aktien/KV-Pharmaceutical-Reports-Record-Revenues-for-Fiscal-2005-Third-Quarte-538702ST. LOUIS, Feb. 1 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company today reported results for the third quarter and nine months of fiscal 2005 ended December 31, 2004.Net revenues for the third quarter increased 25% to $86.9 million, compared to ...http://www.finanzen.net/nachricht/aktien/KV-Pharmaceutical-Reports-Record-Revenues-for-Fiscal-2005-Third-Quarte-538702